Shanghai Henlius Biotech has dosed the first subject in the Phase III clinical trial of Hansizhuang (serplulimab) plus chemotherapy and radiotherapy for limited-stage small cell lung cancer (LS-SCLC) in Europe.
The first subject was dosed in Latvia.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The double-blind, randomised, global, multicentre trial is designed to analyse the safety and efficacy of serplulimab compared to placebo.
Subjects in both arms will receive chemotherapy comprising carboplatin/cisplatin-etoposide and simultaneous radiotherapy.
Assessing the anti-tumour activity of serplulimab plus chemotherapy and radiotherapy is the trial’s primary objective.
The primary endpoint of the study is overall survival while objective response rate, progression-free survival, duration of response, immunogenicity and safety will be the secondary endpoints.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHenlius earlier dosed the first subjects in China, the US, Australia and other countries.
A recombinant humanised anti-PD-1 monoclonal antibody (mAb), Hansizhuang is approved by the China National Medical Products Administration for various oncology indications.
It is indicated for treating ES-SCLC, non-small cell lung cancer, oesophageal squamous cell carcinoma and microsatellite instability-high (MSI-H) solid tumours in China.
More than ten trials of Henlius’s Hansizhuang are underway globally.
In October last year, Henlius obtained the Spanish Agency of Medicines and Medical Devices approval for a Phase III trial of the pertuzumab biosimilar, HLX11.
